



THIS AWARD IS ISSUED UNDER THE AMERICAN RECOVERY AND REINVESTMENT ACT OF 2009 AND IS SUBJECT TO SPECIAL HHS TERMS AND CONDITIONS AS REFERENCED IN SECTION III

Grant Number: 1R15HD066397-01

Principal Investigator(s):

Diane Allen
GAIL L WIDENER (contact), PHD

Project Title: Movement Ability Changes with Balance-Based Torso-Weighting in Multiple Sclerosis

Ms. Sylvester, Sue A
Executive Director of Development
450 30th Street
Oakland, CA 94609

Budget Period: 09/20/2010 – 08/31/2013

Project Period: 09/20/2010 – 08/31/2013

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$399,146 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to SAMUEL MERRITT UNIVERSITY in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release or other document that cites results from NIH grant-supported research must include an acknowledgment of NIH grant support and disclaimer such as "The project described was supported by Award Number R15HD066397 from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute Of Child Health & Human Development or the National Institutes of Health."

Award recipients are required to comply with the NIH Public Access Policy. This includes submission to PubMed Central (PMC), upon acceptance for publication, an electronic version of a final peer-reviewed, manuscript resulting from research supported in whole or in part, with direct costs from National Institutes of Health. The author's final peer-reviewed manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process. For additional information, please visit <http://publicaccess.nih.gov/>.

Award recipients must promote objectivity in research by establishing standards to ensure that the design, conduct and reporting of research funded under NIH-funded awards are not biased by a conflicting financial interest of an Investigator. Investigator is defined as the Principal Investigator and any other person who is responsible for the design, conduct, or reporting of NIH-funded research or proposed research, including the Investigator's spouse and dependent children. Awardees must have a written administrative process to identify and manage financial conflict of interest and must inform Investigators of the conflict of interest policy and of the Investigators' responsibilities. Prior to expenditure of these awarded funds, the Awardee must report to the NIH Awarding Component the existence of a conflicting interest and within 60 days of any new conflicting interests identified after the initial report. Awardees must comply with these and all other aspects of 42 CFR Part 50, Subpart F. These requirements also apply to subgrantees, contractors,

or collaborators engaged by the Awardee under this award. The NIH website <http://grants.nih.gov/grants/policy/coi/index.htm> provides additional information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Margaret A. Young
Grants Management Officer
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN
DEVELOPMENT

Additional information follows

SECTION I – AWARD DATA – 1R15HD066397-01

Award Calculation (U.S. Dollars)

Salaries and Wages	\$79,597
Fringe Benefits	\$27,276
Personnel Costs (Subtotal)	\$106,873
Consultant Services	\$59,345
Equipment	\$2,700
Supplies	\$2,250
Travel Costs	\$9,000
Other Costs	\$2,828
Consortium/Contractual Cost	\$178,711

Federal Direct Costs	\$361,707
Federal F&A Costs	\$37,439
Approved Budget	\$399,146
Federal Share	\$399,146
TOTAL FEDERAL AWARD AMOUNT	\$399,146

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$399,146

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$399,146	\$399,146

Fiscal Information:

CFDA Number: 93.701
 EIN: 1942992642A1
 Document Number: RHD066397Z
 Fiscal Year: 2010

IC	CAN	2010
HD	8485798	\$399,146

NIH Administrative Data:

PCC: SMAD -NS / **OC:** 414A / **Processed:** YOUNGM 09/15/2010

SECTION II – PAYMENT/HOTLINE INFORMATION – 1R15HD066397-01

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 1R15HD066397-01

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.
- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at 'http://grants.nih.gov/grants/policy/awardconditions.htm' for certain references cited above.)

ARRA TERM OF AWARD: This award is subject to the HHS-Approved Standard Terms and Conditions for the American Recovery and Reinvestment Act of 2009. Approved text for NIH

awards can be found at http://grants.nih.gov/grants/policy/NIH_HHS_ARRA_Award_Terms.pdf. Recipients should pay particular attention to the special quarterly reporting requirements required by Section 1512 of the Recovery Act as specified in Term #2.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of [Public Law 110-85](#)), the "responsible party" must register "applicable clinical trials" on the [ClinicalTrials.gov Protocol Registration System Information Website](#). NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

This award represents the final year of the competitive segment for this grant. Therefore, see the NIH Grants Policy Statement (12/1/2003 version) for closeout requirements at: http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part8.htm#_Toc54600151.

A final Financial Status Report (FSR) (SF 269) must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see NIH Guide Notice [NOT-OD-07-078](#) for additional information on this electronic submission requirement. The final FSR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must be no discrepancies between the final FSR and the Payment Management System's (PMS) Federal Cash Transaction Report (SF-272).

Furthermore, unless an application for competitive renewal is submitted, additional grant closeout documents consisting of a Final Invention Statement and Certification form (HHS 568), (not applicable to training, construction, conference or cancer education grants) and a final progress report must also be submitted within 90 days of the expiration date.

NIH also strongly encourages electronic submission of the final progress report and the final invention statement through the Closeout feature in the Commons. If the final progress report and final invention statement are not submitted electronically, copies of the HHS 568 form may be downloaded at: <http://grants.nih.gov/grants/forms.htm>.

Submissions of the final progress report and HHS 568 may be e-mailed as PDF attachments to the NIH Central Closeout Center at: deascentralized@od.nih.gov

Paper submissions of the final progress report and the HHS 568 may be faxed to the NIH Central Closeout Center at 301-480-2304 or mailed to the NIH Central Closeout Center at the following address:

NIH/OD/OER/DEAS
Central Closeout Center
6705 Rockledge Drive, Room 2207
Bethesda, MD 20892-7987 (for regular or U.S. Postal Service Express mail)
Bethesda, MD 20817 (for other courier/express mail delivery only)

The final progress report should include, at a minimum, a summary of progress toward the achievement of the originally stated aims, a list of significant results (positive and/or negative), a list of publications and the grant number. If human subjects were included in the research, the final progress report should also address the following:

- Report on the inclusion of gender and minority study subjects (using the gender and minority Inclusion Enrollment Form as provided in the PHS 2590 and available at <http://grants.nih.gov/grants/forms.htm>).
- Where appropriate, indicate whether children were involved in the study or how the study was relevant for conditions affecting children (see "Public Policy Requirements and Objectives-Requirements for Inclusiveness in Research Design-Inclusion of Children as Subjects in Clinical Research" in the PHS 398 at URL http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part5.htm#_Toc54600090)
- Describe any data, research materials (such as cell lines, DNA probes, animal models), protocols, software, or other information resulting from the research that is available to be shared with other investigators and how it may be accessed.

Note, if this is the final year of a competitive segment due to the transfer of the grant to another institution, then not all the requirements stated above are applicable. Specifically a Final Progress Report is not required. However, a final FSR is required and should be submitted electronically as noted above. In addition, if not already submitted, the Final Invention Statement is required and should be sent directly the assigned Grants Management Specialist.

Treatment of Program Income:
Additional Costs

SECTION IV – HD Special Terms and Conditions – 1R15HD066397-01

RESTRICTION: This award includes \$37,439 for facilities and administrative (F&A) costs. Of this amount, \$29,479 (F&A in excess of 10% of Salaries and Wages) is restricted pending the negotiation of a rate. These restricted funds may not be used for any purpose and may not be carried over to a subsequent budget period without prior approval from NICHD. If the actual negotiated rate is lower than originally estimated, this award may be revised downward.

The grantee should submit an indirect cost rate proposal to the Division of Cost Allocation (DCA) no later than 3 months after the issue date of the grant award. If this proposal is not submitted within this timeframe, the restricted funds will not be released for use in the current budget period and will not be eligible for carryover under the expanded authorities or Federal Demonstration Partnership without the prior written approval of NICHD.

See the NIH Grants Policy Statement, revised December 2003, for a listing of DCA offices (http://grants1.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part14.htm).

RESTRICTION: The present award is being made without a currently valid certification of Institutional Review Board (IRB) approval for this project with the following restriction: Only activities that are clearly severable and independent from activities that involve human subjects may be conducted pending NICHD acceptance of the certification of IRB review and approval.

No funds may be drawn down from the payment system and no obligations may be made against Federal funds for any research involving human subjects prior to NICHD notification to the grantee that the identified issues have been resolved and this restriction removed.

Failure to comply with the above requirements can result in suspension and/or termination of this award, withholding of support, audit disallowances, and/or other appropriate action.

See the NIH Grants Policy Statement, revised December 2003 (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part5.htm) for specific requirements related to the protection of human subjects, which are applicable to and a term and condition of this award.

The NIH requires that all Academic Research Enhancement Awards submit both an annual progress report and a final progress report. The Continuation Progress Report should be sent on or before the anniversary date to:

NICHD/GMB
6100 Executive Boulevard
Room 8A01, MSC 7510
Bethesda, MD 20892-7510 (for regular or U.S. Postal Service Express mail)
Rockville, MD 20852 (for other courier/express mail delivery only)

This award includes funds awarded for consortium activity with San Francisco State University in the amount of \$178,711 (\$116,424 direct costs + \$62,287 facilities and administrative costs). Consortia are to be established and administered as described in the NIH Grants Policy Statement, revised December 2003 (http://grants.nih.gov/grants/policy/nihgps_2003/NIHGPS_Part12.htm#_Toc54600251).

Human Subjects: NICHD recognizes that investigators are submitting applications to conduct exciting and important research of interest to NICHD. NICHD has oversight responsibilities to ensure compliance with government regulations and to ensure the safety of human subjects in research. The following Web site contains information regarding your institutional responsibilities and compliance issues that should be reviewed throughout the duration of your NIH-supported project. DHHS Web Site for Human Subjects: <http://www.hhs.gov/ohrp/>.

The grantee institution bears ultimate responsibility for protecting human subjects under this award, including human subjects at all participating and consortium sites, and for ensuring that a Federalwide Assurance approved by the Office of Human Research Protection and certification of Institutional Review Board review and approval have been obtained before human subjects research can be conducted at each site. The documentation of these assurances should be kept on file at the grantee institution. If requested, this documentation should be submitted to NICHD.

The grantee is required to follow the Multiple Principal Investigator Leadership Plan included in the application dated 10/27/2009 and may not implement any changes in the plan without the written prior approval of NICHD.

Although the signatures of all PIs are not required on prior approval requests submitted to NICHD, the grantee institution must secure and retain the signatures of all of PIs within their own internal processes. See NIH Guide Notice NOT-OD-06-054 (<http://grants.nih.gov/grants/guide/notice-files/NOT-OD-06-054.html>).?

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Jennifer Tucker
Email: jennifer.tucker@nih.hhs.gov **Phone:** 301-443-8291

Program Official: Nancy Shinowara
Email: shinowara@nih.gov **Phone:** (301) 435-6838 **Fax:** (301) 402-0832

SPREADSHEET SUMMARY

GRANT NUMBER: 1R15HD066397-01

INSTITUTION: SAMUEL MERRITT UNIVERSITY

<i>Budget</i>	<i>Year 1</i>
Salaries and Wages	\$79,597
Fringe Benefits	\$27,276
Personnel Costs (Subtotal)	\$106,873
Consultant Services	\$59,345
Equipment	\$2,700
Supplies	\$2,250
Travel Costs	\$9,000
Other Costs	\$2,828
Consortium/Contractual Cost	\$178,711
TOTAL FEDERAL DC	\$361,707
TOTAL FEDERAL F&A	\$37,439
TOTAL COST	\$399,146

<i>Facilities and Administrative Costs</i>	<i>Year 1</i>
F&A Cost Rate 1	18%
F&A Cost Base 1	\$207,996

